Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
AstraZeneca
Biotech
AstraZeneca's ph. 3 cancer fail is latest blow to ATR inhibitors
The failure is another blow to efforts to use a synthetic lethal mechanism to overcome resistance to immuno-oncology drugs.
Nick Paul Taylor
Dec 22, 2025 4:35am
AstraZeneca fronts $100M for Jacobio's pan-KRAS inhibitor
Dec 22, 2025 4:31am
AZ's latest amyloidosis pact with Neurimmune could reach $780M
Dec 4, 2025 8:00am
AstraZeneca's $1.3B bet reduced BP by 14 mmHg over 12 weeks
Nov 10, 2025 6:15am
Axsome adds AZ asset through Avenue subsidiary acquisition
Nov 6, 2025 10:50am
AstraZeneca drops MASH drug over disappointing data
Nov 6, 2025 5:21am
